Ernexa Therapeutics Inc. (NASDAQ:ERNA) on Wednesday said an independently conducted preclinical study validated the anti-tumor activity of its lead cell therapy candidate, ERNA-101, when combined with PD-1 checkpoint inhibition, reinforcing earlier findings.
• Ernexa Therapeutics stock is showing exceptional strength. What’s fueling ERNA momentum?
The cell therapy company prepares for an Investigational New Drug application later this year.
According to the company, the independent study reproduced previous research conducted at The University of Texas Anderson Cancer Center in a larger cohort, demonstrating complete tumor clearance and durable long-term survival.
Ernexa said the findings provide third-party support for ERNA-101’s mechanism of action, as it targets an IND submission in the third quarter of 2026 and plans to begin a first-in-human phase one clinical trial in the fourth quarter.
